France Clinical Oncology NGS Market (2025-2031) | Analysis, Industry, Outlook, Value, Share, Forecast, Size & Revenue, Companies, Competitive Landscape, Growth, Trends, Segmentation

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3.1 France Country Macro Economic Indicators

3.2 France Clinical Oncology NGS Market Revenues & Volume, 2021 & 2031F

3.3 France Clinical Oncology NGS Market - Industry Life Cycle

3.4 France Clinical Oncology NGS Market - Porter's Five Forces

3.5 France Clinical Oncology NGS Market Revenues & Volume Share, By Technology, 2021 & 2031F

3.6 France Clinical Oncology NGS Market Revenues & Volume Share, By Workflow, 2021 & 2031F

3.7 France Clinical Oncology NGS Market Revenues & Volume Share, By Application, 2021 & 2031F

3.8 France Clinical Oncology NGS Market Revenues & Volume Share, By End-use, 2021 & 2031F

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing prevalence of cancer cases in France, driving the demand for advanced oncology treatments like NGS.

4.2.2 Technological advancements in Next Generation Sequencing (NGS) technologies, making them more efficient and cost-effective in clinical oncology applications.

4.2.3 Growing focus on personalized medicine and targeted therapies in oncology, driving the adoption of NGS for molecular profiling and treatment selection.

4.3 Market Restraints

4.3.1 High initial setup costs associated with NGS technology implementation and infrastructure in clinical oncology settings.

4.3.2 Data privacy and security concerns related to the storage and sharing of sensitive genetic information gathered through NGS in oncology.

4.3.3 Regulatory hurdles and compliance challenges in the adoption of NGS technologies for clinical use in oncology.

6.1 France Clinical Oncology NGS Market, By Technology

6.1.1 Overview and Analysis

6.1.2 France Clinical Oncology NGS Market Revenues & Volume, By Technology, 2021- 2031F

6.1.3 France Clinical Oncology NGS Market Revenues & Volume, By Whole Genome Sequencing, 2021- 2031F

6.1.4 France Clinical Oncology NGS Market Revenues & Volume, By Whole Exome Sequencing, 2021- 2031F

6.1.5 France Clinical Oncology NGS Market Revenues & Volume, By Targeted Sequencing & Resequencing Centrifuges, 2021- 2031F

6.2 France Clinical Oncology NGS Market, By Workflow

6.2.1 Overview and Analysis

6.2.2 France Clinical Oncology NGS Market Revenues & Volume, By Pre-Sequencing, 2021- 2031F

6.2.3 France Clinical Oncology NGS Market Revenues & Volume, By Sequencing, 2021- 2031F

6.2.4 France Clinical Oncology NGS Market Revenues & Volume, By Data Analysis, 2021- 2031F

6.3 France Clinical Oncology NGS Market, By Application

6.3.1 Overview and Analysis

6.3.2 France Clinical Oncology NGS Market Revenues & Volume, By Screening, 2021- 2031F

6.3.3 France Clinical Oncology NGS Market Revenues & Volume, By Companion Diagnostics, 2021- 2031F

6.3.4 France Clinical Oncology NGS Market Revenues & Volume, By Other Diagnostics, 2021- 2031F

6.4 France Clinical Oncology NGS Market, By End-use

6.4.1 Overview and Analysis

6.4.2 France Clinical Oncology NGS Market Revenues & Volume, By Hospitals, 2021- 2031F

6.4.3 France Clinical Oncology NGS Market Revenues & Volume, By Clinics, 2021- 2031F

6.4.4 France Clinical Oncology NGS Market Revenues & Volume, By Laboratories, 2021- 2031F

7.1 France Clinical Oncology NGS Market Export to Major Countries

7.2 France Clinical Oncology NGS Market Imports from Major Countries

8.1 Average turnaround time for NGS testing in clinical oncology settings.

8.2 Rate of adoption of NGS-based molecular profiling in treatment decision-making for cancer patients.

8.3 Percentage increase in research and development investments in NGS technologies for clinical oncology applications.

8.4 Number of partnerships and collaborations between NGS technology providers and healthcare institutions in France for oncology research and clinical applications.

8.5 Improvement in the accuracy and sensitivity of NGS-based diagnostics for oncology over time.

9.1 France Clinical Oncology NGS Market Opportunity Assessment, By Technology, 2021 & 2031F

9.2 France Clinical Oncology NGS Market Opportunity Assessment, By Workflow, 2021 & 2031F

9.3 France Clinical Oncology NGS Market Opportunity Assessment, By Application, 2021 & 2031F

9.4 France Clinical Oncology NGS Market Opportunity Assessment, By End-use, 2021 & 2031F

10.1 France Clinical Oncology NGS Market Revenue Share, By Companies, 2024

10.2 France Clinical Oncology NGS Market Competitive Benchmarking, By Operating and Technical Parameters